Clene Inc.

AdCom AI-extracted

CNM-Au8

amyotrophic lateral sclerosis (ALS)

Resolved

7days ago

Advisory committee · ~ Jun 30, 2026 estimated

What's at stake An FDA advisory committee reviews CNM-Au8 for amyotrophic lateral sclerosis (ALS) around ~ Jun 30, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.

Primary source · SEC 8-K verified 17h ago

“The Company plans to file an accelerated approval New Drug Application (“NDA”) in amyotrophic lateral sclerosis (“ALS”).”

Add to calendar Post on X Reddit

Provenance